Amy Ruschulte, MD
Family Medicine · Cincinnati, OHNPI 1700848496
Payments from drug & device makers
Across 122 payments — averaging $18.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$438
- Abbott$289
- Novo Nordisk$288
- Lilly USA, LLC$178
- GSK$157
- Pfizer$132
- plus $715 from 22 others
What the payments were for
- Food & beverage$2,14798%
- Education$502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $438 |
| Abbott | 14 | $289 |
| Novo Nordisk | 18 | $288 |
| Lilly USA, LLC | 12 | $178 |
| GSK | 10 | $157 |
| Pfizer | 9 | $132 |
| Exact Sciences | 3 | $73 |
| Currax Pharmaceuticals LLC | 3 | $63 |
| Boehringer Ingelheim | 4 | $60 |
| Amgen | 3 | $55 |
| AstraZeneca | 4 | $53 |
| Merck | 3 | $53 |
| Pulmonx Corporation | 1 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Sanofi Pasteur Inc. | 2 | $30 |
| Eisai Inc. | 1 | $28 |
| Lundbeck LLC | 1 | $25 |
| Ironshore Pharmaceuticals Inc. | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
How this compares
$2,197 in reported general payments places this provider in the 75th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 83 | $100,419 |
| JardianceEmpagliflozin | 28 | $35,517 |
| MounjaroTirzepatide | 34 | $35,390 |
| XareltoRivaroxaban | 29 | $34,884 |
| JanuviaSitagliptin Phosphate | 12 | $19,934 |
| EliquisApixaban | 12 | $19,352 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $15,424 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $11,626 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,573 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 19 | $2,792 |
| Atorvastatin Calcium | 367 | $2,697 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $2,237 |
| Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm | 11 | $2,079 |
| Metoprolol Succinate | 146 | $2,033 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $1,776 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $288 | $100,41983 claims |
| Boehringer IngelheimJardiance | $60 | $35,51728 claims |
| Lilly USA, LLCMounjaro | $178 | $35,39034 claims |
| Johnson & JohnsonXarelto | $14 | $34,88429 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $157 | $19,99724 claims |
| MerckJanuvia | $53 | $19,93412 claims |
| PfizerEliquis | $132 | $19,35212 claims |
| AbbVieSynthroid | $438 | $1,36040 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Cincinnati
- Michael ButcherCincinnati$18.3M
- Paul NugentCincinnati$4.9M
- Rajesh DavitCincinnati$2M
- Michael HeileCincinnati$272K
- Michael NossCincinnati$265K
- Amy MechleyCincinnati$120K
- Melissa SchroerCincinnati$116K
- William CoxCincinnati$52K
- Frank PerrinoCincinnati$49K
- Sean LyndCincinnati$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.